Advanced clinical-stage pipeline
Two first-in-class products in clinical development
Contact us for additional medical and product information:
Charcot-Marie-Tooth Disease type 1A (CMT1A)
PXT3003 is a novel synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral solution given twice daily.
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice daily.
Have a question for Pharnext?
Want to join our team?
Subject of your request?
I have a question
I want to join the team
I want a company update